Dyne Therapeutics Inc DYN
NASDAQ · United States · Health Technology
$15.73-0.10 (-0.60%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) shares gained 2.1% in after-hours trading Tuesday following the release of one-year trial data for its experimental DM1 treatment z-basivarsen.
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months - - Data continued to support improvement at 6 months in video hand opening time (vHOT) as an early indicator of clinical benefit with z-basivarsen in DM1 - - Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registra
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.